{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:48:55Z","timestamp":1759452535510,"version":"build-2065373602"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To better understand the symptoms and impacts of Raynaud phenomenon (RP) in patients with systemic sclerosis (SSc) and to evaluate the content validity and usability of a new electronic patient\u2010reported outcome (PRO) measure for RP: the Raynaud Diary.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Raynaud Diary was developed as a daily eDiary for assessing the number and duration of symptomatic Raynaud attacks; worst pain, numbness, tingling, and discomfort in the fingers; and overall disease severity, captured using the Raynaud's Condition Score. The Raynaud Diary was debriefed in two waves of qualitative interviews with adults with self\u2010reported RP secondary to SSc. All interviews included open\u2010ended questions about participants' experiences of RP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Participants (N\u00a0=\u00a039) had a mean age of 55.1\u2009years, and 87% were female. Frequently reported RP symptoms were color change (reported by all participants), numbness (90%), tingling (82%), pain (77%), and discomfort (72%). Common attack triggers included temperature\u2010related factors and stress. Participants reported being unable to be outside or do outdoor activities and had problems gripping objects. All participants demonstrated understanding of the Raynaud Diary instructions. Most participants indicated that they would be able to use the Raynaud Diary to record the worst severity of individual RP symptoms in the previous 24 hours.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with RP secondary to SSc bear a heavy symptom burden. The Raynaud Diary is a content valid PRO measure that captures the most frequent symptoms of RP in patients with SSc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11522","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T07:55:37Z","timestamp":1675324537000},"page":"132-141","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-0922","authenticated-orcid":false,"given":"Robyn T.","family":"Domsic","sequence":"first","affiliation":[{"name":"University of Pittsburgh  Pennsylvania Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Pokrzywinski","sequence":"additional","affiliation":[{"name":"Evidera  Maryland Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa","family":"Stassek","sequence":"additional","affiliation":[{"name":"Evidera  Maryland Bethesda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wade W.","family":"Benton","sequence":"additional","affiliation":[{"name":"Eicos Sciences, Inc  California San Mateo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa\u2010Lynn","family":"Vampola","sequence":"additional","affiliation":[{"name":"Eicos Sciences, Inc  California San Mateo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-2373","authenticated-orcid":false,"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[{"name":"University of California  Los Angeles California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[{"name":"Stanford University  California Palo Alto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Steen","sequence":"additional","affiliation":[{"name":"Georgetown University  D.C Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5070-2535","authenticated-orcid":false,"given":"Maureen D.","family":"Mayes","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center  Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami A.","family":"Shah","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine  Maryland Baltimore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry A.","family":"Molitor","sequence":"additional","affiliation":[{"name":"University of Minnesota  Minneapolis Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Oliver","sequence":"additional","affiliation":[{"name":"Eicos Sciences, Inc  California San Mateo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-3200","authenticated-orcid":false,"given":"Vivek","family":"Nagaraja","sequence":"additional","affiliation":[{"name":"University of Michigan Scleroderma Program  Ann Arbor Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Eicos Sciences, Inc., San Mateo, California, and University of Michigan Scleroderma Program  Ann Arbor Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(94)90323-9"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-3-199402010-00004"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10895"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834ff2e8"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp013013"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0386-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199611000-00011"},{"key":"e_1_2_8_9_1","first-page":"12","article-title":"Digital ulceration and critical digital ischemia in scleroderma","volume":"1","author":"Denton C","year":"2003","journal-title":"Scleroderma Care Res"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10486"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.107706"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key026"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23475"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.952"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020909529486"},{"key":"e_1_2_8_16_1","unstructured":"FDA.Guidance for industry: patient\u2010reported outcome measures: use in medical product development to support labeling claims. URL:https:\/\/www.fda.gov\/media\/77832\/download."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401110"},{"key":"e_1_2_8_19_1","first-page":"1630","article-title":"Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6","volume":"30","author":"Merkel PA","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/2397198318774307"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11522","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:24:02Z","timestamp":1759422242000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/acr2.11522"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11522","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"type":"print","value":"2578-5745"},{"type":"electronic","value":"2578-5745"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"2022-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}